Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pharmacokinetics
100%
Mycobacterium Tuberculosis (M. tb)
100%
Rabbit Model
100%
Rifampin
100%
Clinical Trial Data
100%
Rifapentine
100%
Tuberculosis Patients
37%
Cavitary Lesion
37%
Site of Disease
25%
Penetration Coefficient
25%
Pharmacokinetic/pharmacodynamic Model
25%
Mouse Model
12%
Lung
12%
Clinical Trials
12%
Clinical Pharmacology
12%
Site of Action
12%
Phase I Trial
12%
Drug Pharmacokinetics
12%
Treatment Outcome
12%
Multiple Dose
12%
Plasma Exposure
12%
Minimum Inhibitory Concentration
12%
Sputum Culture Conversion
12%
Large Cavity
12%
Bacteria Count
12%
Drug Distribution
12%
Cavitary Tuberculosis
12%
Lung Cavity
12%
Cavity Wall
12%
Rabbit Lungs
12%
Rifamycin Antibiotics
12%
Lesion Penetration
12%
Cavitary Lung Disease
12%
Drug Penetration
12%
Cavitary Lung Lesion
12%
Caseum
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Rifampicin
100%
Rabbit Model
100%
Rifapentine
100%
Pharmacokinetics
100%
Tuberculosis
100%
Leporidae
25%
Drug Induced Disease
25%
Mouse Model
12%
Antibiotics
12%
Pharmacodynamics
12%
Clinical Pharmacokinetics
12%
Lung Disease
12%
Lung Tuberculosis
12%
Mycobacterium Tuberculosis
12%
Lung Lesion
12%
Drug Distribution
12%
Minimum Inhibitory Concentration
12%
Rifamycin
12%
Pharmacodynamic Modeling
12%
Lung Cavity
12%
Bacterium
12%
Neuroscience
Pharmacokinetics
100%
Tuberculosis
100%
Rifapentine
100%
Blood Plasma
25%
Rifamycin Antibiotics
12%